Raymond James & Associates’s Kite Pharma, Inc. KITE Stock Holding History

Raymond James & Associates’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-13,012	Closed	-$2.34M	–	3611
2017 Q3	$2.34M	Buy	13,012 +478	+4%	+$66.6K	﹤0.01%	1543
2017 Q2	$1.3M	Sell	12,534 -5,332	-30%	-$435K	﹤0.01%	1854
2017 Q1	$1.4M	Buy	17,866 +5,587	+46%	+$345K	﹤0.01%	1770
2016 Q4	$551K	Buy	12,279 +5,973	+95%	+$293K	﹤0.01%	2278
2016 Q3	$352K	Buy	+6,306	New	+$351K	﹤0.01%	2513
2016 Q2	–	Sell	-6,469	Closed	-$297K	–	3138
2016 Q1	$297K	Buy	+6,469	New	+$313K	﹤0.01%	2342

Raymond James & Associates's KITE Position: Q4 2017 in Review

Raymond James & Associates sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 13,012 shares — an estimated $2.34M sold.

Raymond James & Associates first reported a position in KITE in Q1 2016 and held it in 6 quarters. The position peaked at $2.34M in Q3 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.

Raymond James & Associates reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
Raymond James & Associates sold 13,012 Kite Pharma, Inc. shares in Q4 2017, an estimated $2.34M.
Raymond James & Associates first reported a position in Kite Pharma, Inc. in Q1 2016 and held it in 6 quarters.
Raymond James & Associates's Kite Pharma, Inc. position peaked at $2.34M in Q3 2017.
0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.

Based on Raymond James & Associates's 13F filing for Q4 2017, filed 14 Feb 2018.